Clementia Pharmaceuticals Joins Global Patient Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day MONTREAL, CANADA, April 23, 2015 – Clementia Pharmaceuticals, Inc. today joins patients, their families, patient organizations and the scientific community in recognizing and supporting Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day 2015. Led by the International FOP Association (IFOPA), FOP Awareness Day is observed annually on April 23 to increase awareness of the disease and commemorate the day the gene that causes FOP was discovered. FOP is a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare‐ups) that result in the formation of new, abnormal (heterotopic) bone in muscles, tendons and ligaments. This heterotopic bone progressively restricts movement by locking joints and leads to cumulative loss of function and disability. On April 23, 2006, researchers from the University of Pennsylvania School of Medicine identified a mutation of a gene for a receptor called ACVR1 as the cause for abnormal bone formation. “The discovery of the gene mutation was a watershed moment for the FOP community, and was instrumental in the identification of potential treatment targets,” said Clarissa Desjardins, Ph.D., Chief Executive Officer of Clementia. “Clementia is honored to be working hand in hand with researchers and patients toward a common goal of finding a treatment option for this devastating disease, and we are thankful for the tireless contributions of the community.” For more information about FOP Awareness Day, visit http://www.ifopa.org/news‐and‐
events/international‐fop‐awareness‐day.html. About Fibrodysplasia Ossificans Progressiva (FOP) FOP is a rare, severely disabling congenital myopathy characterized by painful, recurrent episodes of soft tissue swelling (flare‐ups) that result in new, abnormal bone formation in muscles, tendons, and ligaments. Flare‐ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare‐ups progressively restrict movement by locking joints, leading to cumulative loss of function and disability. FOP is caused by a point mutation in the ALK2/BMP type I receptor; the mutation results in over‐ activity of the receptor. Virtually all known patients have the same point mutation and have congenital malformations of the big toes at birth. FOP is thought to affect less than one individual for every million lives. About Clementia Pharmaceuticals, Inc. Clementia is a privately held, clinical‐stage biopharmaceutical company focused on developing and commercializing innovative therapies for people living with rare diseases. The company is advancing a novel retinoic acid receptor gamma agonist to address diseases of heterotopic ossification, including fibrodysplasia ossificans progressiva. For more information, please visit www.clementiapharma.com. Investor/Media Contact: Smitha Dwarakanath SmithSolve LLC 973‐442‐1555 ext. 122 Source: Clementia Pharmaceuticals, Inc. ###